contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment CompanyTagList on Company {
  pageUrl
  name
  viewerIsFollowing
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    ...CompanyTagList
    id
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls {
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      defaultInstrument {
        isin
        id
      }
      id
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    id
    name
    viewerIsFollowing
    defaultInstrument {
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


__typename

title

isPremium

lang

htmlBody

companies

createdAt

publishers

authors

reactionGroups

pageUrl

alternatePageUrls

imgUrl

description

Bone Support is active in medical technology. The company develops and commercializes injectable bioceramic bone graft substitutes that are transformed into the patient's bone and have the ability to release drugs. The company's bone graft substitutes are based on the technology platform Cerament. At present, the company conducts ongoing clinical studies. The company has sales in Europe and North America and is headquartered in Lund, Sweden.

Bonesupport

Dr. Michael Diefenbeck, Chief Medical Officer and EVP Clinical Affairs, has sold 30,000 shares, with the sole purpose to cover tax effects of the distributed shares from the employee 2016 stock...

<div class="mfn-body"><p>Dr. Michael Diefenbeck, Chief Medical Officer and EVP Clinical Affairs, has sold 30,000 shares, with the sole purpose to cover tax effects of the distributed shares from the employee 2016 stock options program. After the transaction, his total ownership of shares in BONESUPPORT™ has increased with 24,000 shares to 108,160. </p></div><div class="mfn-footer mfn-contacts mfn-c708d7131d79"><p><strong class="mfn-heading-1">For more information contact:</strong></p><hr><p>BONESUPPORT Holding AB<br>Emil Billbäck, CEO<br>+46 (0) 46 286 53 70</p><p>Håkan Johansson, CFO<br>+46 (0) 46 286 53 70<br><a rel="noopener" href="mailto:ir@bonesupport.com">ir@bonesupport.com</a></p><p>Cord Communications<br>Charlotte Stjerngren<br>+46 (0) 708 76 87 87<br><a rel="noopener" href="mailto:charlotte.stjerngren@cordcom.se">charlotte.stjerngren@cordcom.se</a><br><a rel="noopener" href="http://www.cordcom.se">www.cordcom.se</a></p></div><div class="mfn-footer mfn-about mfn-a24a17574e02"><p><strong class="mfn-heading-1">About BONESUPPORT™</strong></p><hr><p>BONESUPPORT (Nasdaq Stockholm: BONEX) develops and commercializes innovative injectable bio-ceramic bone graft substitutes that remodel to the patient’s own bone and have the capability of eluting drugs. BONESUPPORT’s bone graft substitutes are based on the patented technology platform <a rel="noopener" href="https://bonesupport.com/en-eu/products/">CERAMENT</a>. The company is conducting several clinical studies to further demonstrate the clinical and health economic benefits its products deliver. The company is based in Lund, Sweden, and the net sales amounted to SEK 591 million in 2023. Please visit <a rel="noopener" href="http://www.bonesupport.com/">www.bonesupport.com</a> for more information.<br>BONESUPPORT and CERAMENT are <a rel="noopener" href="https://bonesupport.com/en-eu/trademarks/">registered trademarks</a> of BONESUPPORT AB.</p></div><div class="mfn-footer mfn-attachment mfn-attachment-general"><p><strong class="mfn-heading-1">Attachments</strong></p><hr><p><a rel="noopener" href="https://storage.mfn.se/285394ba-11f2-4c0a-b462-a64ae9d94c97/announced-insider-trading.pdf" class="mfn-generated mfn-primary">Announced Insider Trading</a></p></div>

Announced Insider Trading

Federal Reserven korkopäätös: Kiire loppui tähän

Drug development investment: Value creation through M&As and licensing agreements

Euroalueen ostopäälliköt: Onks sen jälkeen vielä mäki?

EKP:n korkopäätös: Keskuspankki ilman rajoitteita

Laskuviikko takana Euroopassa, EKP:n viesti sai lopulta velkakirjakorot nousuun

Stay up to date with our newsletter